Molecular analysis of the INK4 family of genes in prostate carcinomas

Journal of Urology

Volumn 157, Issue 5, 1997, Pages 1995-1999

  Park, Dorothy J ^a   Wilczynski, Sharon P ^b   Pham, Emily Y ^b   Miller, Carl W ^b   Phillip Koeffler, H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

cyclin dependent kinase inhibitor; mutation; prostate neoplasms; tumor suppressor genes

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0030976031     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64917-6     Document Type: Article

References (59)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo,P. A.: Cancer statistics, 1996. CA Cancer J. Clin., 46: 5, 1996.
2. Hirama,T. and Koeffler,H. P.: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86: 841, 1995.
3. Hunter,T. and Pines,J.: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell, 79: 573, 1994.
4. Marx,J.: How cells cycle toward cancer. Science, 263: 319, 1994.
5. Matthias,P. and Herskowitz,I.: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell, 79: 181, 1994.
6. Sherr,C. J.: Mammalian G1 cyclins. Cell, 73: 1059, 1993.
7. Serrano, M., Hannon,G. J. and Beach,D.: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366: 704, 1993.
8. INK4B is a potential effector of TGF-B-induced cell cycle arrest. Nature, 371: 257, 1994.
9. INK4B/MTS2-related CDK6 inhibitor, correlate with wild-type pRb function. Genes Dev., 8: 2939, 1994.
10. Hirai,H., Roussel,M. F., Kato,J.-Y., Ashmun,R. A. and Sherr, C. J.: Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15: 2672, 1995.
11. Chan,F. K. M., Zhang,J., Cheng,L., Shapiro, D. N. and Winoto, A.: Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16 INK4. Mol. Cell. Biol., 15: 2682, 1995.
12. El-Deiry, W. S., Tokinao, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B.: WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817, 1993.
13. Gu, Y., Turck, C. W. and Morgan, D. O.: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 366: 257, 1993.
14. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J.: The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805, 1993.
15. Hunter, T.: Braking the cycle. Cell, 75: 839, 1993.
16. Xiong, Y., Hannon, G. J., Zang, H., Casso, D., Kobayashi, R. and Beach, D.: p21 is a universal inhibitor of cyclin kinases. Nature, 366: 701, 1993.
17. Kip 1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59, 1994.
18. Toyoshima, H. and Hunter, T.: p27, a novel ingibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell, 78: 67, 1994.
19. KIIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639, 1995.
20. Cairns, P., Mao, L., Merlo, A., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E. and Sidransky, D.: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 265: 415, 1994.
21. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. and Kern, S. E.: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet., 8: 27, 1994.
22. Coleman, A., Fountain, J. W., Nobori, T., Olufunmilayo, I. O., Robertson, G., Housman, D. E. and Lugo, G. L.: Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res., 54: 344, 1994.
23. Fountain, J. W., Karayiorgou, M., Ernstoff, M. S., Kirkwood, J. M., Vlock, D. R., Titus-Ernsthoff, L., Bouchard, B., Vijayasaradhi, S., Houghton, A. N., Lahti, J., Kidd, V. J., Housman, D. E. and Dracopoli, N. C.: Homozygous deletions of human chromosome 9p21 in melanoma. Proc. Natl. Acad. Sci. USA, 89: 10557, 1992.
24. Hayashi, N., Sugimoto, Y., Tsuchija, E., Ogawa, M. and Nakamura, Y.: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun., 202: 1426, 1994.
25. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H. J., Tucker, M. A. and Dracopoli, N. C.: Germline p16 mutations in familial melanoma. Nature Genet., 8: 15, 1994.
26. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E. and Skolnick, M. H.: A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264: 436, 1994.
27. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., Zone, J. J., Skolnick, M. H. and Cannon-Albright, L. A.: Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8: 22, 1994.
28. Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S. and Nakamura, Y.: Frequent somatic 1mutation of the MTS1/ CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396, 1994.
29. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, A. D.: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368: 753, 1994.
30. Spruck, C. H., Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M. M., Gonzales, F., Tsai, Y. C. and Jones, P. A.: p16 gene in uncultured tumors. Nature, 370: 183, 1994.
31. INK4 protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene, 9: 3375, 1994.
32. Hebert, J., Cayuela, J. M., Berkeley, J. and Sigaux, F.: Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood, 84: 4038, 1994.
33. Ogawa, S., Hirano, N., Sato, N., Takahashi, T., Hangaishi, A., Tanaka, K., Kurokawa, M., Tanaka, T., Mitani, K., Yazaki, Y. and Hirai, H.: Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood, 84: 2431, 1994.
34. Quesnel, B., Preudhomme, C., Philippe, N., Vanrumbeke, M., Dervite, I., Lai, J. L., Bauters, F., Wattel, E. and Fenaux, P.: p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood, 85: 657, 1995.
35. Takeuchi, S., Bartram, C. R., Seriu, T., Miller, C. W., Tobler, A., Janssen, J. W. G., Reiter, A., Ludwig, W.-D., Zimmermann, M., Schwaller, J., Lee, E., Miyoshi, I. and Koeffler, H. P.: Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood, 86: 755, 1995.
36. Nakamaki, T., Kawamata, N., Schwaller, J., Tobler, A., Fey, M., Pakkala, S., Lee, Y. Y., Kim, B. K., Fukuchi, K., Tsuruoka, N., Kahan, J., Miller, C. W. and Koeffler, H. P.: Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. Br. J. Haematol., 91: 139, 1995.
37. Shiohara, M., Spirin, K., Said, J. W., Gombart, A. F., Nakamaki, T., Takeuchi, S., Hatta, Y., Morosetti, R., Tasaka, T., Seriu, T., Bartram, C., Miller, C. W., Tomonaga, M. and Koeffler, H. P.: Molecular analysis of the cyclin-dependent kinase inhibitor p19INK4D in hematopoietic malignancies. J. Cancer Res. Clin. Oncol., 1221: 559, 1996.
38. Spirin, K. S., Simpson, J. F., Miller, C. W. and Koeffler, H. P.: Molecular analysis of INK4 genes in breast carcinomas. Submitted.
39. Ausebel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K.: Current Protocols in Molecular Biology. 3rd ed. New York: Greene Publishing Associates, Inc. and Wiley & Sons, 1993.
40. Johnson, K. R., Nousseef, W. M., Care, A., Wheelock, M. J., Hudson, S., Koeffler, H. P., Selsted, M., Miller, C. and Rovera, G.: Characterization of cDNA clones for human myeloperoxidase: predicted amino acid sequence and evidence for multiple mRNA species. Nucleic Acids Res., 15: 2013, 1987.
41. Orita, M., Suzuki, Y., Sekiya, T. and Hayashi, K.: Rapid and sensitive detection of point mutations and genetic polymorphisms using polymerase chain reaction. Genomics, 5: 874, 1989.
42. Kawamata, N., Miller, C. W. and Koeffler, H. P.: Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4B and p18/INK4C) in non-small cell lung cancers. Mol. Carcinogen., 14: 263, 1995.
43. Miller, C. W., Yeon, C., Aslo, A., Mendoza, S., Aytac, U., Lampkin, B. C. and Koeffler, H. P.: The p19 cyclin dependent kinase inhibitor gene is mutated and rearranged in osteosarcoma. Submitted.
44. Anwar, K., Nakakuki, K., Shiraishi, T., Naiki, H., Yatani, R. and Inuzuka, M.: Presence of ras oncogene mutations and human papilloma virus DNA in human prostate carcinoma. Cancer Res., 52: 5991, 1992.
45. Brooks, J. D., Bova, G. S. and Isaacs, W. B.: Allelic loss of the retinoblastoma gene in primary human prostatic carcinoma. Prostate, 26: 35, 1995.
46. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. and Allred, D. C.: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res., 53: 3369, 1993.
47. Visakorpi, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T. and Isola, J.: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst., 84: 883, 1992.
48. Komiya, A., Suzuki, H., Aida, S., Yatani, R. and Shimazaki, J.: Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn. J. Cancer Res., 86: 622, 1995.
49. INK4a tumor suppressor protein. Cancer Res., 55: 2503, 1995.
50. INK4B in non-Hodgkin's lymphomas. Blood, 86: 1534, 1995.
51. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D. and Sidransky, D.: Frequency of homozygous deletion at p16/ CDKN2 in primary human tumors. Nature Genet., 11: 210, 1995.
52. Hatta, Y., Hirama, T., Miller, C. W., Yamada, Y., Tomonaga, M. and Koeffler, H. P.: Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood, 85: 2699, 1995.
53. Tasaka, T., Berenson, J., Vescio, R., Hirama, T., Miller, C. W., Nagai, M., Takahara, J. and Koeffler, H. P.: Analysis of the INK4 family of genes in multiple myeloma. Br. J. Haematol., 96: 98, 1997.
54. Little, M. and Wainwright, B.: Methylation and p16: suppressing the suppressor. Nature Med., 1: 633, 1995.
55. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J.-P. J., Davidson, N. E., Sidransky, D. and Baylin, S. B.: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525, 1995.
56. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M. and Jones, P. A.: Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531, 1995.
57. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B. and Sidransky, D.: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med., 1: 686, 1995.
58. Otterson, G. A., Kkhleif, S. N., Chen, W., Coxon, A. B. and Kaye, F. J.: CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene, 11: 1211, 1995.
59. Shapiro, G. I., Park, J. E., Edwards, C. D., Mao, L., Merlo, A., Sidransky, D., Ewen, M. E. and Rollins, B. J.: Multiple mechanisms of p16 INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res., 55: 6200, 1995.